Early Breast Cancer: New Findings Through Subgroup And Biomarker Analyses

by Konstantin Dedes | 5 September 2024 | Women's Cancers

Study data presented at the 2024 ASCO Congress demonstrate that CDK4/6 inhibitors and other therapies are effective in treating early breast cancer within specific subgroups. New biomarker data can also refine treatment algorithms. In patients with hormone receptor...

FDA Expands Cancer Treatment Options with New Drug Approvals

by FDA Approval | 15 August 2024 | Solid Tumors, Women's Cancers

The U.S. Food and Drug Administration (FDA) has recently expanded its indications and granted approvals for three drugs, offering new options for patients with various forms of cancer. The approved drugs—dostarlimab-gxly for endometrial cancer, afamitresgene...

HER2-Expressing Gynecological Cancers: Catching Up on Targeted Approaches

by Ilaria Colombo | 19 July 2024 | Women's Cancers

Compared to other tumor types, the development of HER2-targeted therapies for gynecological malignancies is lagging somewhat behind. Nevertheless, promising data have already been generated in the treatment of endometrial, cervical, and ovarian cancer.  © Freepik |...

EU Recommends New Treatments for Endometrial and Urothelial Cancers

by EMA Approval | 12 July 2024 | Urogenital, Women's Cancers

The European Union has recommended new treatment options for patients with primary advanced or recurrent endometrial cancer and metastatic urothelial carcinoma. Durvalumab and Olaparib have been endorsed for endometrial cancer based on positive trial results, while...

Capivasertib Plus Fulvestrant Gains EU Approval for Advanced Breast Cancer

by EMA Approval | 20 June 2024 | Women's Cancers

Capivasertib, in combination with fulvestrant, has received approval from the European Union (EU) for treating adult patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer. This approval targets patients with specific...

FDA Approves New Drugs for Endometrial Cancer and Ph-Negative BCP ALL

by FDA Approval | 18 June 2024 | Women's Cancers

The Food and Drug Administration (FDA) has approved new treatments for endometrial cancer and Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (Ph-negative BCP ALL). These advancements promise to enhance therapeutic options and improve...